EA
ABUS icon

Emerald Advisers’s Arbutus Biopharma ABUS Stock Holding History

Emerald Advisers’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-10,847
Closed -$142K – 347
2014
Q2 		$142K Sell
10,847
-4,403
-29% -$62.4K 0.01% 377
2014
Q1 		$328K Buy
15,250
+50
+0.3% +$898 0.02% 311
2013
Q4 		$121K Buy
+15,200
New +$127K 0.01% 345

Other funds holding ABUS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Emerald Advisers's ABUS Position: Q3 2014 in Review

Emerald Advisers sold out of Arbutus Biopharma (ABUS) in Q3 2014, closing a stake of 10,847 shares — an estimated $142K sold.

Emerald Advisers first reported a position in ABUS in Q4 2013 and held it in 3 quarters. The position peaked at $328K in Q1 2014. 48 funds tracked by Wall St. Rank hold ABUS as of Q3 2014.

  • Emerald Advisers reported no remaining Arbutus Biopharma position as of Q3 2014 after selling out during the quarter.
  • Emerald Advisers sold 10,847 Arbutus Biopharma shares in Q3 2014, an estimated $142K.
  • Emerald Advisers first reported a position in Arbutus Biopharma in Q4 2013 and held it in 3 quarters.
  • Emerald Advisers's Arbutus Biopharma position peaked at $328K in Q1 2014.
  • 48 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2014.

Based on Emerald Advisers's 13F filing for Q3 2014, filed 28 Oct 2014.